anastrozole has been researched along with Disease Exacerbation in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane." | 9.17 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013) |
| "These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment." | 9.15 | Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. ( Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y, 2011) |
| "A total of 16 premenopausal women with metastatic breast cancer (N=13) or locally advanced primary breast cancer (N=3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole." | 9.11 | Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. ( Cheung, KL; Forward, DP; Jackson, L; Robertson, JF, 2004) |
| "Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment." | 9.08 | Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. ( Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM, 1996) |
| "The aim of this study was to compare the efficacy and tolerability of the new aromatase inhibitor 'ARIMIDEX' (anastrozole) with megestrol acetate in the treatment of advanced breast cancer in postmenopausal women." | 9.08 | A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. ( Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G, 1996) |
| " Only RCTs that compared fulvestrant 250 mg to anastrozole 1mg in postmenopausal women with advanced breast cancer were selected." | 8.90 | Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. ( Fan, Y; Gong, DD; Man, CF; Xu, J, 2014) |
| "We did a meta-analysis of three clinical trials--the Austrian Breast and Colorectal Cancer Study Group (ABCSG 8), Arimidex-Nolvadex (ARNO 95), and the Italian Tamoxifen Anastrozole (ITA) studies--in which postmenopausal women with histologically confirmed, hormone-sensitive early-stage breast cancer were randomised to 1 mg/day anastrozole (n=2009) after 2-3 years of tamoxifen treatment or to continued 20 or 30 mg/day tamoxifen (n=1997)." | 8.83 | Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. ( Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I, 2006) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 7.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 7.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane." | 5.17 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013) |
| "These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment." | 5.15 | Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. ( Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y, 2011) |
| "A total of 16 premenopausal women with metastatic breast cancer (N=13) or locally advanced primary breast cancer (N=3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole." | 5.11 | Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. ( Cheung, KL; Forward, DP; Jackson, L; Robertson, JF, 2004) |
| "This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex')." | 5.10 | Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. ( Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I, 2003) |
| "Formestane (Lentaron) and anastrozole (Arimidex) are in clinical use as second-line treatments for advanced breast cancer." | 5.09 | Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. ( Coombes, RC; Harper-Wynne, C, 1999) |
| "Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment." | 5.08 | Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. ( Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM, 1996) |
| "The aim of this study was to compare the efficacy and tolerability of the new aromatase inhibitor 'ARIMIDEX' (anastrozole) with megestrol acetate in the treatment of advanced breast cancer in postmenopausal women." | 5.08 | A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. ( Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G, 1996) |
| " Only RCTs that compared fulvestrant 250 mg to anastrozole 1mg in postmenopausal women with advanced breast cancer were selected." | 4.90 | Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. ( Fan, Y; Gong, DD; Man, CF; Xu, J, 2014) |
| "We did a meta-analysis of three clinical trials--the Austrian Breast and Colorectal Cancer Study Group (ABCSG 8), Arimidex-Nolvadex (ARNO 95), and the Italian Tamoxifen Anastrozole (ITA) studies--in which postmenopausal women with histologically confirmed, hormone-sensitive early-stage breast cancer were randomised to 1 mg/day anastrozole (n=2009) after 2-3 years of tamoxifen treatment or to continued 20 or 30 mg/day tamoxifen (n=1997)." | 4.83 | Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. ( Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I, 2006) |
| "Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen)." | 4.80 | The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. ( Hamilton, A; Piccart, M, 1999) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 3.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 3.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "The ABCSG-12 trial investigated the efficacy of gonadotropin-releasing hormone (GnRH)analogs in combination with tamoxifen or anastrozole + or - zoledronic acid (4 mg, q6m for 3 years) in 1,803 premenopausal women with hormone receptor-positive (HR+) breast cancer." | 3.76 | Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. ( Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D, 2010) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer." | 3.73 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. ( Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F, 2005) |
| " This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR)." | 3.71 | Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? ( Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM, 2001) |
| "A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER⁺)." | 2.90 | PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; DeFazio, A; Friedlander, M; Goh, J; Grant, P; Kok, PS; Mapagu, C; O'Connell, RL; Scurry, J; Sjoquist, K, 2019) |
| "Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down-regulates the ER and has no known agonist effects." | 2.71 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. ( Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A, 2003) |
| "HER2-positive breast cancer accounts for 20 to 25% of breast cancers." | 2.46 | [Management of metastatic HER2-positive breast cancer: present and future]. ( Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S, 2010) |
| "From the group with therapy change, 'disease progression' was reason of change in 124 (58." | 1.62 | Switching of Hormone Therapies in Breast Cancer Women. ( Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R, 2021) |
| "The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008." | 1.38 | Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012) |
| "Twelve patients (15%) had disease progression while taking PHT." | 1.37 | Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? ( Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E, 2011) |
| "Anastrozole was ineffective at preventing deterioration of renal function in this patient." | 1.35 | Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. ( Bohrer, J; Chen, CC; Falcone, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 16 (39.02) | 29.6817 |
| 2010's | 18 (43.90) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Buus, R | 1 |
| Sestak, I | 1 |
| Barron, S | 1 |
| Loughman, T | 1 |
| Fender, B | 1 |
| Ruiz, CL | 1 |
| Dynoodt, P | 1 |
| Wang, CA | 1 |
| O'Leary, D | 1 |
| Gallagher, WM | 1 |
| Dowsett, M | 2 |
| Cuzick, J | 1 |
| Medeiros, LM | 1 |
| Stahlschmidt, R | 1 |
| Ferracini, AC | 1 |
| Souza, CM | 1 |
| Juliato, CRT | 1 |
| Mazzola, PG | 1 |
| Ogasa, Y | 1 |
| Kuwamura, T | 1 |
| Akiyoshi, T | 1 |
| Murakami, S | 1 |
| Tanaka, H | 1 |
| Umeda, S | 1 |
| Suematsu, F | 1 |
| Kok, PS | 1 |
| Beale, P | 1 |
| O'Connell, RL | 1 |
| Grant, P | 1 |
| Bonaventura, T | 1 |
| Scurry, J | 1 |
| Antill, Y | 1 |
| Goh, J | 1 |
| Sjoquist, K | 1 |
| DeFazio, A | 1 |
| Mapagu, C | 1 |
| Amant, F | 1 |
| Friedlander, M | 1 |
| Munoz, J | 1 |
| Kumar, VA | 1 |
| Hamilton, J | 1 |
| Pasche, LJ | 1 |
| Langford, LA | 1 |
| Taggart, MW | 1 |
| Kamiya-Matsuoka, C | 1 |
| Tummala, S | 1 |
| Moulder, S | 1 |
| Kurzrock, R | 1 |
| Johnston, SR | 1 |
| Kilburn, LS | 1 |
| Ellis, P | 1 |
| Dodwell, D | 1 |
| Cameron, D | 1 |
| Hayward, L | 1 |
| Im, YH | 1 |
| Braybrooke, JP | 1 |
| Brunt, AM | 1 |
| Cheung, KL | 2 |
| Jyothirmayi, R | 1 |
| Robinson, A | 1 |
| Wardley, AM | 1 |
| Wheatley, D | 1 |
| Howell, A | 6 |
| Coombes, G | 1 |
| Sergenson, N | 1 |
| Sin, HJ | 1 |
| Folkerd, E | 1 |
| Bliss, JM | 1 |
| Grella, E | 1 |
| La Padula, S | 1 |
| Romanucci, V | 1 |
| Nicoletti, GF | 1 |
| D'Andrea, F | 1 |
| Gong, DD | 1 |
| Man, CF | 1 |
| Xu, J | 1 |
| Fan, Y | 1 |
| Lewis, L | 1 |
| Taylor, M | 1 |
| Suriya Ertugyrovna, Y | 1 |
| Kuanysh Shadybayevich, N | 1 |
| Kaldygul Kabakovna, S | 1 |
| Ramil Zufarovich, A | 1 |
| van Meurs, HS | 1 |
| van der Velden, J | 1 |
| Buist, MR | 1 |
| van Driel, WJ | 1 |
| Kenter, GG | 1 |
| van Lonkhuijzen, LR | 1 |
| Shankar, A | 1 |
| Roy, S | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Kamal, VK | 1 |
| Malik, A | 1 |
| Patil, J | 1 |
| Jeyaraj, PA | 1 |
| Mahajan, MK | 1 |
| Beauchemin, C | 1 |
| Letarte, N | 1 |
| Mathurin, K | 1 |
| Yelle, L | 1 |
| Lachaine, J | 1 |
| Gershenson, DM | 1 |
| Bodurka, DC | 1 |
| Coleman, RL | 1 |
| Lu, KH | 1 |
| Malpica, A | 1 |
| Sun, CC | 1 |
| Nemitz, N | 1 |
| Kurmann, PT | 1 |
| Van Linthoudt, D | 1 |
| Bohrer, J | 1 |
| Chen, CC | 1 |
| Falcone, T | 1 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Guiu, S | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Arnould, L | 1 |
| Fumoleau, P | 1 |
| Lux, MP | 1 |
| Reichelt, C | 1 |
| Wallwiener, D | 1 |
| Kreienberg, R | 1 |
| Jonat, W | 5 |
| Gnant, M | 2 |
| Beckmann, MW | 1 |
| Thiel, FC | 1 |
| Xu, B | 1 |
| Jiang, Z | 1 |
| Shao, Z | 1 |
| Wang, J | 1 |
| Feng, J | 1 |
| Song, S | 1 |
| Chen, Z | 1 |
| Gu, K | 1 |
| Yu, S | 1 |
| Zhang, Y | 1 |
| Wang, C | 1 |
| Zhang, F | 1 |
| Yang, J | 1 |
| Osborn, G | 1 |
| Jones, M | 1 |
| Champ, C | 1 |
| Gower-Thomas, K | 1 |
| Vaughan-Williams, E | 1 |
| Wink, CJ | 1 |
| Woensdregt, K | 1 |
| Nieuwenhuijzen, GA | 1 |
| van der Sangen, MJ | 1 |
| Hutschemaekers, S | 1 |
| Roukema, JA | 1 |
| Tjan-Heijnen, VC | 1 |
| Voogd, AC | 1 |
| Williams, S | 1 |
| Michael, B | 1 |
| Mewar, D | 1 |
| Tunn, E | 1 |
| Glück, S | 2 |
| von Minckwitz, G | 1 |
| Untch, M | 1 |
| Vergote, I | 3 |
| Stasi, R | 1 |
| Terzoli, E | 1 |
| Thornton, H | 1 |
| Campos, SM | 1 |
| Winer, EP | 1 |
| Robertson, JF | 3 |
| Kleeberg, U | 1 |
| Burton, G | 1 |
| Osborne, CK | 2 |
| Mauriac, L | 3 |
| Jones, SE | 3 |
| Ellis, M | 1 |
| Kleeberg, UR | 1 |
| Come, SE | 1 |
| Gertler, S | 1 |
| Buzdar, A | 2 |
| Webster, A | 3 |
| Morris, C | 1 |
| Forward, DP | 1 |
| Jackson, L | 1 |
| Bertelli, G | 1 |
| Garrone, O | 1 |
| Merlano, M | 1 |
| Occelli, M | 1 |
| Bertolotti, L | 1 |
| Castiglione, F | 1 |
| Pepi, F | 1 |
| Fusco, O | 1 |
| Del Mastro, L | 1 |
| Leonard, RC | 1 |
| Boccardo, F | 1 |
| Kaufmann, M | 1 |
| Rubagotti, A | 1 |
| Zuna, I | 1 |
| Greenwood, M | 1 |
| Jakesz, R | 1 |
| Blomqvist, C | 2 |
| Vogel, CL | 2 |
| Eiermann, W | 3 |
| Wolter, JM | 2 |
| Azab, M | 2 |
| Plourde, PV | 1 |
| Winblad, G | 1 |
| Tyrrell, C | 1 |
| Roche, H | 1 |
| Lundgren, S | 1 |
| Hellmund, R | 1 |
| Buzdar, AU | 1 |
| Blomqvist, CP | 1 |
| Steinberg, M | 1 |
| Lee, D | 1 |
| Hamilton, A | 1 |
| Piccart, M | 1 |
| Harper-Wynne, C | 1 |
| Coombes, RC | 1 |
| Carlini, P | 1 |
| Frassoldati, A | 1 |
| De Marco, S | 1 |
| Casali, A | 1 |
| Ruggeri, EM | 1 |
| Nardi, M | 1 |
| Papaldo, P | 1 |
| Fabi, A | 1 |
| Paoloni, F | 1 |
| Cognetti, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-[NCT00253422] | Phase 3 | 750 participants (Anticipated) | Interventional | 2004-03-31 | Active, not recruiting | ||
| A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-st[NCT00944918] | Phase 3 | 25 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer[NCT00327769] | Phase 3 | 234 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for anastrozole and Disease Exacerbation
| Article | Year |
|---|---|
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2014 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2013 |
Hormonal therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progre | 2003 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Su | 2006 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
11 trials available for anastrozole and Disease Exacerbation
24 other studies available for anastrozole and Disease Exacerbation
| Article | Year |
|---|---|
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Pro | 2020 |
Switching of Hormone Therapies in Breast Cancer Women.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Dise | 2021 |
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Pro | 2018 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Co | 2013 |
Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: clinical and surgical management.
Topics: Anastrozole; Aromatase Inhibitors; Breast; Child; Combined Modality Therapy; Disease Progression; Di | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuv | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2017 |
[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2008 |
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Topics: Anastrozole; Aromatase Inhibitors; Disease Progression; Endometriosis; Female; Humans; Kidney Functi | 2008 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breas | 2010 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; | 2010 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2001 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estra | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopl | 2001 |